KRAS and colorectal carcinoma: In fact, a recent study analyzing the efficacy of colonoscopy depending on the molecular subtype of tumors in the general population showed a weaker CRC risk reduction after colonoscopy for KRAS wild-type tumors [63]; (2) Alternatively, oncogene-activating missense mutations, which need to affect very specific nucleotides and therefore have a lower likelihood per genome replication than indel mutations, may be less frequent in tumors with rapid evolution and short progression times such as incident cancers [64].